Granata Bio concludes screening in Phase III GRACE trial for IVF
Granata Bio has completed participant screening in its Phase III GRACE trial of Granata Bio human menopausal gonadotropin (GB-hMG) in …
Post
-
-
Roivant eyes Lisraya label expansion on Phase III uveitis win
Roivant and its subsidiary, Priovant Therapeutics, have scored another late-stage win for their marketed ophthalmology therapy, Lisraya (brepocitinib), in non-infectious …
-
HealthBio begins multi-centre trial of Inflamexa for PTLDS
US-based biotechnology company HealthBio has initiated a multi-centre clinical trial, HBT-002, to assess its lead compound Inflamexa in adult patients …
-
Podcast: Do PI signatures really signal meaningful oversight?
As clinical trial oversight has moved online as technology is more utilised in clinical trials, it brings up some questions …
-
Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
The US Food and Drug Administration (FDA) has authorised Lynch Regenerative Medicine’s investigational new drug (IND) application for a Phase …
-
Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
The US Food and Drug Administration (FDA) has authorised Lynch Regenerative Medicine’s investigational new drug (IND) application for a Phase …
-
Covid-19 and international aid cuts disrupt tuberculosis care in South Africa
South Africa suffers from a disproportionately severe disease burden of tuberculosis (TB), which is one of the country’s leading causes …
-
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Sanofi and Teva Pharmaceuticals’ inflammatory bowel disease (IBD) drug has shown benefit in patients with both ulcerative colitis (UC) and …
-
Amgen and AstraZeneca report Phase III Tezspire data for EoE
Amgen and AstraZeneca have reported complete results from the Phase III CROSSING clinical trial of Tezspire (tezepelumab-ekko) for adolescent and …
-
Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit
Shionogi and F2G are releasing further data from a non-inferiority study of the latter's oral invasive aspergillosis drug, showing its …
-
AstraZeneca and Oracle collaborate to test AI in clinical trial recruitment
AstraZeneca and Oracle have signed a non-binding agreement to investigate how AI and real-world data can help medical teams recruit …
-
ESMO26: HUTCHMED and AstraZeneca share positive outlook on NSCLC trials
HUTCHMED and AstraZeneca will use the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid …
-
Rapport’s novel oral drug posts Phase II bipolar win
Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market …
-
EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals has announced sweeping job cuts after its eye disease candidate, duravyu, failed to meet its key goal during …
-
Veradermics’ stock up on male hair loss trial success
Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair loss drug …
